When the world’s best HIV prevention tool meets the planet’s deadliest infectious disease

South Africa’s rollout of the twice-yearly HIV prevention injection lenacapavir could transform the fight against HIV, but its success will depend on navigating the country’s equally severe TB epidemic. Because some of the most commonly used TB medicines reduce lenacapavir’s effectiveness, researchers and health officials are developing strategies to keep people protected while filling critical evidence gaps.